The investment will be used to complete development of the company's Idus bimodal ultrasound technology. The technology combines anatomical 2D imaging with real-time acoustic stimulation paradigms to image, detect, locate in 3D, and classify micron-size targets. The technology could be useful for visualizing breast premalignant lesions, such as clusters and grouped microcalcifications.
Idus is compatible with both automated hands-free volumetric ultrasound scanners and conventional systems with handheld transducers, the company said. Quantason plans to begin clinical trials soon, with the goal of developing a commercial product for use in women's imaging.
The company also said it plans to relocate its headquarters from Philadelphia to Los Angeles next month.
Copyright © 2012 AuntMinnie.com